Bank of New Hampshire Trims Stock Holdings in Pfizer Inc. (NYSE:PFE)

Bank of New Hampshire decreased its stake in Pfizer Inc. (NYSE:PFE) by 43.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 6,977 shares of the biopharmaceutical company’s stock after selling 5,284 shares during the quarter. Bank of New Hampshire’s holdings in Pfizer were worth $201,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Briaud Financial Planning Inc purchased a new position in Pfizer during the 3rd quarter valued at approximately $30,000. Mizuho Securities Co. Ltd. bought a new stake in shares of Pfizer in the 3rd quarter valued at approximately $34,000. VisionPoint Advisory Group LLC lifted its stake in shares of Pfizer by 52,350.0% in the 3rd quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock valued at $35,000 after purchasing an additional 1,047 shares during the last quarter. GoalVest Advisory LLC lifted its stake in shares of Pfizer by 304.9% in the 4th quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock valued at $31,000 after purchasing an additional 811 shares during the last quarter. Finally, Tennessee Valley Asset Management Partners bought a new stake in shares of Pfizer in the 4th quarter valued at approximately $36,000. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on PFE shares. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $45.00 target price on shares of Pfizer in a research report on Monday, April 15th. Guggenheim started coverage on Pfizer in a research report on Friday, February 23rd. They set a “buy” rating and a $36.00 price target for the company. TD Cowen cut Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price target for the company. in a research report on Thursday, January 4th. Finally, Argus cut Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. Eleven research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $36.33.

Pfizer Price Performance

Shares of PFE stock traded down $1.00 during trading hours on Thursday, reaching $25.27. The company had a trading volume of 47,095,453 shares, compared to its average volume of 41,949,781. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.69 and a current ratio of 0.91. The stock has a fifty day moving average of $27.05 and a 200-day moving average of $28.50. The company has a market capitalization of $143.09 billion, a price-to-earnings ratio of 71.14, a PEG ratio of 1.19 and a beta of 0.61. Pfizer Inc. has a 12-month low of $25.23 and a 12-month high of $40.37.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.29. The business had revenue of $14.25 billion during the quarter, compared to analyst estimates of $14.37 billion. Pfizer had a return on equity of 10.88% and a net margin of 3.62%. The business’s revenue was down 41.3% compared to the same quarter last year. During the same period in the prior year, the business earned $1.14 earnings per share. On average, equities analysts anticipate that Pfizer Inc. will post 2.24 earnings per share for the current year.

Pfizer Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 14th. Investors of record on Friday, May 10th will be given a $0.42 dividend. The ex-dividend date is Thursday, May 9th. This represents a $1.68 annualized dividend and a yield of 6.65%. Pfizer’s payout ratio is 466.67%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.